Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA Approves BiTE Therapy for Adults and Children with Leukemia Subtype
Blinatumomab has received full approval from the FDA after long-term data confirmed its safety and efficacy.
Research
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
PALO ALTO, Calif., June 7, 2023 – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage oncology company dedicated to the discovery …
News
FDA Approves New Bispecific Antibody for Non-Hodgkin Lymphoma Subtype
Epcoritamab gives patients with diffuse large B-cell lymphoma another treatment option.
News
FDA Approves Therapy to Decrease Infection Risk Following Stem Cell Transplant
“This new treatment is a big step forward that may help improve patient outcomes,” said LLS Chief Scientific Officer Lee Greenberger, Ph.D. “LLS was o…
News
FDA Approves Treatment for Patients Newly Diagnosed with Most Common Lymphoma
“The FDA’s decision gives newly diagnosed patients with this aggressive form of lymphoma their first new treatment option in nearly two decades,” says…
Research
Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
BERKELEY, Calif., April 04, 2023 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company,…
News
FDA Approves New Formulation of Important Childhood Leukemia Drug
The U.S. Food and Drug Administration yesterday approved nelarabine injection, a critical treatment for T-cell acute lymphoblastic leukemia (T-ALL), a…
News
FDA Approves New Type of BTK Inhibitor to Treat Mantle Cell Lymphoma
The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first non-covalent, reversable BTK inhibitor for the treatment of …
News
FDA Approves the First-in-Class Bispecific Antibody for Treatment of Follicular Lymphoma
“This new treatment has the potential to help patients with this hard-to-treat cancer achieve remission,” says LLS Chief Scientific Officer Dr. Lee Gr…
News
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
Research
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
BERKELEY, Calif., Nov. 29, 2022 - Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, …
